Observations highlight the significance of experienced professionals in drug development for biotech start-ups, suggesting a shift in focus from pure science to expertise.
The traditional perception that scientific innovation alone determines the success of biotechnology start-ups is increasingly challenged by the growing complexity of modern drug development. While breakthrough science remains essential, the ability to efficiently transform a scientific concept into a clinically and regulatorily credible asset has become equally—if not more—dependent on the experience and execution capabilities of the development team.
No takes yet. Share an insight, caveat, or question.
b François-Xavier Lacassea (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: